文献速递胸部肿瘤

白细胞介素-17A通过招募中性粒细胞至肿瘤部位并介导PD-1阻断耐药促进肺肿瘤进展

Interleukin-17A Promotes Lung Tumor Progression through Neutrophil Attraction to Tumor Sites and Mediating Resistance to PD-1 Blockade.
PubMed 文献 · J Thorac Oncol · 2017-05-06

在IL-17A与KrasG12D条件表达双转基因小鼠中,IL-17A过表达使肺肿瘤生长更快、生存期显著缩短,并增加肿瘤相关中性粒细胞、减少淋巴细胞募集。PD-1阻断对IL-17:KrasG12D肿瘤无效,而阻断IL-6或清除中性粒细胞可产生与T细胞活化相关的临床反应。肺腺癌患者数据中,KRAS突变肿瘤的高IL-17A与集落刺激因子3水平相关,高中性粒细胞数与低T细胞数显著相关。

要点

  • IL-17A过表达加速KrasG12D小鼠肺肿瘤生长并显著缩短生存期。
  • IL-17:KrasG12D小鼠中PD-1阻断无效,阻断IL-6或清除中性粒细胞可产生临床反应。
  • KRAS突变肺癌患者中高IL-17A与集落刺激因子3相关,高中性粒细胞与低T细胞数显著相关。

核心结论

  • 单一细胞因子IL-17A升高无需额外突变即可通过促进炎症促进肺癌生长,导致PD-1阻断耐药,并使肿瘤对细胞因子阻断和中性粒细胞清除敏感。

研究设计与样本

  • 构建条件性IL-17A等位基因与条件性KrasG12D共表达的双转基因小鼠,进行小鼠肺免疫表型分析、生存分析和抗体治疗研究。
  • 治疗研究使用阻断PD-1、阻断IL-6或清除中性粒细胞的抗体。
  • 分析人类基因表达数据集并对患者肺肿瘤进行免疫表型分析以支持临床前发现。

主要发现

  • IL-17:KrasG12D小鼠肿瘤生长较KrasG12D小鼠更快,生存期显著缩短。
  • IL-17:KrasG12D小鼠肺内IL-6、粒细胞集落刺激因子(G-CSF)、乳脂球-EGF因子8蛋白和C-X-C基序趋化因子配体1升高。
  • 时间进程分析显示IL-17:KrasG12D小鼠较KrasG12D小鼠肿瘤相关中性粒细胞水平显著升高、淋巴细胞募集显著减少。
  • 治疗研究中PD-1阻断对IL-17:KrasG12D肿瘤无效;阻断IL-6或用抗Ly-6G抗体清除中性粒细胞可使IL-17:KrasG12D肿瘤产生与T细胞活化相关的临床反应。
  • KRAS突变肺癌患者肿瘤中,较高IL-17A水平与集落刺激因子3相关,高中性粒细胞数与低T细胞数之间显著相关。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Proinflammatory cytokine interleukin-17A (IL-17A) is overexpressed in a subset of patients with lung cancer. We hypothesized that IL-17A promotes a protumorigenic inflammatory phenotype and inhibits antitumor immune responses. METHODS: We generated bitransgenic mice expressing a conditional IL-17A allele along with conditional KrasG12D and performed immune phenotyping of mouse lungs, a survival analysis, and treatment studies with antibodies either blocking programmed cell death 1 (PD-1) or IL-6 or depleting neutrophils. To support the preclinical findings, we analyzed human gene expression data sets and immune profiled patient lung tumors. RESULTS: Tumors in IL-17:KrasG12D mice grew more rapidly, resulting in a significantly shorter survival as compared with that of KrasG12D mice. IL-6, granulocyte colony-stimulating factor (G-CSF), milk fat globule-EGF factor 8 protein, and C-X-C motif chemokine ligand 1 were increased in the lungs of IL17:Kras mice. Time course analysis revealed that levels of tumor-associated neutrophils were significantly increased, and lymphocyte recruitment was significantly reduced in IL17:KrasG12D mice as compared with in KrasG12D mice. In therapeutic studies PD-1 blockade was not effective in treating IL-17:KrasG12D tumors. In contrast, blocking IL-6 or depleting neutrophils with an anti-Ly-6G antibody in the IL17:KrasG12D tumors resulted in a clinical response associated with T-cell activation. In tumors from patients with lung cancer with KRAS mutation we found a correlation between higher levels of IL-17A and colony- stimulating factor 3 and a significant correlation among high neutrophil and lower T-cell numbers. CONCLUSIONS: Here we have shown that an increase in a single cytokine, IL-17A, without additional mutations can promote lung cancer growth by promoting inflammation, which contributes to resistance to PD-1 blockade and sensitizes tumors to cytokine and neutrophil depletion.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Akbay EA, Koyama S, Liu Y, et al. Interleukin-17A Promotes Lung Tumor Progression through Neutrophil Attraction to Tumor Sites and Mediating Resistance to PD-1 Blockade. J Thorac Oncol. 2017. PMID: 28483607. doi:10.1016/j.jtho.2017.04.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。